ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

IRBM, MD Anderson ink antibody development pact

by Rick Mullin
September 14, 2019 | APPEARED IN VOLUME 97, ISSUE 36

IRBM has signed a service and development agreement with the University of Texas MD Anderson Cancer Center to develop monoclonal antibodies targeting a novel immune checkpoint. The two will combine their discovery technologies to identify and validate lead antibodies through preclinical proof of concept studies. IRBM will use its phage display antibody libraries and immuno-oncology capabilities to generate and optimize fully human antibody candidates against the undisclosed target.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment